Susceptibility of Candida spp. of clinical origin to lucknomycin, a new polyenic antibiotic.
Lucknomycin is a new polyenic derivative antifungal agent obtained from a Streptomyces diastatochromogenes culture. The in vitro activity of the compound was tested against 403 strains of different Candida species of clinical origin by the Sabouraud Agar dilution method. The mean geometrical value of the minimal inhibitory concentrations (MIC) for Candida albicans was 0.85 microgram/ml, 6 times lower than the corresponding value of nystatin (5.29 micrograms/ml) and very close to that of amphotericin B (0.56 microgram/ml). Lucknomycin was also 4-10 times more active than nystatin on other Candida species, with an MIC similar to those obtained with amphotericin B.